Sunshine Biopharma (SBFM) Invested Capital (2011 - 2022)

Sunshine Biopharma (SBFM) has reported Invested Capital for 12 consecutive years, with $21.6 million the latest figure, recorded in Q4 2022.

• For the quarter ending Q4 2022, Invested Capital rose 924.2% year-over-year to $21.6 million; the trailing twelve-month figure through Dec 2022 stood at $21.6 million (up 924.2% YoY), and the FY2022 full-year result was $21.6 million, up 924.2% from the prior year.
• Invested Capital declined to $21.6 million in Q4 2022 per SBFM's latest filing, from $40.4 million in the prior quarter.
• Across five years, Invested Capital topped out at $41.9 million in Q2 2022 and bottomed at -$195199.0 in Q1 2020.
• Historically, Invested Capital has averaged $6.4 million across 5 years, with a median of $783945.5 in 2018.
• The sharpest annual moves came in 2020 and 2022: Invested Capital tumbled 123.71% in 2020, then soared 2671.16% in 2022.
• Over 5 years, Invested Capital stood at $653757.0 in 2018, then tumbled by 122.8% to -$149078.0 in 2019, then jumped by 646.44% to $814623.0 in 2020, then surged by 159.22% to $2.1 million in 2021, then jumped by 924.2% to $21.6 million in 2022.
• According to Business Quant data, Invested Capital over the past three periods registered $21.6 million, $40.4 million, and $41.9 million for Q4 2022, Q3 2022, and Q2 2022 respectively.